Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
[Theme Stocks] East Asia ST, the gastric inflammation treatment "Styrene Q Tablets" license application promotes the stock price to rise
East Asia ST is gaining momentum after submitting a domestic product license application for the treatment drug for acute and chronic gastritis, “Steluren Q Tablets.”
According to data from the Korea Exchange, East Asia ST closed at 46,400 KRW. This was up 1,000 KRW (2.20%) from the previous trading day’s closing price of 45,400 KRW.
East Asia ST’s announcement states that it has submitted a product license application for “Steluren Q Tablets” to the Korea Food and Drug Safety Ministry. Steluren Q Tablets have the same active ingredient as the existing representative product Steluren Tablets, but the dosing frequency has been reduced from the original 2–3 times per day to 1 time per day, making it an improved formulation.
The market tends to view this license application not only as a simple new product launch procedure, but also as material that can enhance brand competitiveness in existing gastritis treatment drugs. This is because improved ease of administration can help increase patients’ medication adherence, and for the company, it is expected to have the effect of broadening its gastritis treatment drug product portfolio.
Previously, East Asia ST said that in a Phase 3 clinical trial conducted from January 2024 to July 2025 with a total of 467 subjects, Steluren Q Tablets were proven to be non-inferior to the original Steluren Tablets. Among the primary evaluation indicators, the lower bound of the confidence interval was -13.87%, exceeding the non-inferiority margin value (-14%), and no significant differences were confirmed in safety either.
The company plans to begin selling domestically in the future after obtaining approval from the Food and Drug Safety Ministry and completing health insurance drug price registration. This move can be interpreted as a strategic extension aimed at maintaining and expanding its market dominance by improving the dosage form of its existing core product.